Research programme: wound healing therapy - CytRx

Drug Profile

Research programme: wound healing therapy - CytRx

Alternative Names: Wound healing therapy research programme - Biorex

Latest Information Update: 05 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biorex; CytRx Corporation
  • Developer Biorex
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic wounds

Most Recent Events

  • 05 Dec 2008 Discontinued - Preclinical for Chronic wounds in Hungary (unspecified route)
  • 13 Oct 2004 Biorex has been acquired by CytRx Corporation
  • 08 Sep 2000 Preclinical development for Chronic wounds in Hungary (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top